Daewoong Pharmaceutical holds Nabota event in Argentina; 200 Latin American medical professionals attend
- Input
- 2026-10-20 09:02:36
- Updated
- 2026-10-20 09:02:36
Daewoong Pharmaceutical Co., Ltd. said on the 20th that it held the “Nabota Master Class (NMC) LATAM 2026” in Buenos Aires, Argentina, on the 13th and 14th. This was the first time the event had been held in Latin America. About 200 medical professionals from six countries, including Brazil, Argentina, Chile, Ecuador, Peru and Panama, attended. Seven invited speakers from Korea, Latin America and the United Arab Emirates (UAE) shared their clinical experience.
The event covered injection strategies that take into account the anatomical characteristics and facial-expression patterns of Latino patients. Key topics included lifting and skin-quality improvement procedures using Nabota, as well as functional anatomy relevant to treating hyperhidrosis and performing masseter procedures. A live demonstration also featured a technique combining botulinum toxin with skin boosters.
According to Daewoong Pharmaceutical Co., Ltd., Nabota has been launched in 12 Latin American countries, including Brazil, Argentina, Chile and Peru, since its entry into Panama in 2015. South American sales grew by an average of 20% annually over the past three years. Nabota was the first Korean-made botulinum toxin product to receive product approval in Argentina.
According to market research firm Grand View Research, the Latin American aesthetic injectables market was valued at $520.3 million in 2025 and is projected to grow by an average of 9.0% annually through 2033. The forecast average annual growth rate for the Argentine market over the same period is 9.3%.
Yoon Jun-su, head of the Nabota Business Division at Daewoong Pharmaceutical Co., Ltd., said, “We will expand educational programs that reflect regional medical environments and academic needs, and continue exchanges with medical professionals around the world.”
[email protected] Jeong Sang-hee Reporter